EA202192646A1 - Лиофилизированная композиция, содержащая соединение бензоазепина - Google Patents

Лиофилизированная композиция, содержащая соединение бензоазепина

Info

Publication number
EA202192646A1
EA202192646A1 EA202192646A EA202192646A EA202192646A1 EA 202192646 A1 EA202192646 A1 EA 202192646A1 EA 202192646 A EA202192646 A EA 202192646A EA 202192646 A EA202192646 A EA 202192646A EA 202192646 A1 EA202192646 A1 EA 202192646A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lyophilized composition
composition containing
benzoazepine compound
benzoazepine
compound
Prior art date
Application number
EA202192646A
Other languages
English (en)
Inventor
Такакуни Мацуда
Нобутомо Сако
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA202192646A1 publication Critical patent/EA202192646A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Air Humidification (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Обеспечивается состав, стабильно содержащий пролекарство толваптана. В частности, предусматривается лиофилизированная композиция, содержащая соединение, соответствующее формуле (1)или его соль металла и дисахарид.
EA202192646A 2019-03-28 2020-03-27 Лиофилизированная композиция, содержащая соединение бензоазепина EA202192646A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019064347 2019-03-28
PCT/JP2020/013924 WO2020196814A1 (en) 2019-03-28 2020-03-27 Benzoazepine compound-containing freeze-dried composition

Publications (1)

Publication Number Publication Date
EA202192646A1 true EA202192646A1 (ru) 2021-12-09

Family

ID=70289831

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192646A EA202192646A1 (ru) 2019-03-28 2020-03-27 Лиофилизированная композиция, содержащая соединение бензоазепина

Country Status (7)

Country Link
US (1) US20220249523A1 (ru)
EP (1) EP3946259A1 (ru)
JP (2) JP7043156B2 (ru)
KR (1) KR20210144810A (ru)
CN (1) CN113645954B (ru)
EA (1) EA202192646A1 (ru)
WO (1) WO2020196814A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7319730B2 (ja) * 2020-09-23 2023-08-02 株式会社ユニバーサルエンターテインメント 遊技機

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004206A1 (en) 2005-12-27 2010-01-07 Makoto Komatsu Water-soluble benzoazepine compound and its pharmaceutical composition
JP5590780B2 (ja) 2007-06-26 2014-09-17 大塚製薬株式会社 医薬
CN101716149B (zh) * 2009-11-30 2013-04-10 宜昌人福药业有限责任公司 一种新的前体药物制剂
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物

Also Published As

Publication number Publication date
JP7043156B2 (ja) 2022-03-29
CN113645954B (zh) 2024-03-29
US20220249523A1 (en) 2022-08-11
KR20210144810A (ko) 2021-11-30
CN113645954A (zh) 2021-11-12
JP2022517115A (ja) 2022-03-04
EP3946259A1 (en) 2022-02-09
JP2022081630A (ja) 2022-05-31
WO2020196814A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MY192703A (en) Compositions containing tucaresol or its analogs
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
TN2009000398A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds
MX2017011711A (es) Mejora en o con relacion a compuestos organicos.
WO2019120234A3 (zh) 作为溴结构域蛋白质抑制剂的化合物和组合物
MX2009003926A (es) Composiciones de fenilalquilamino-carbamato.
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2021014680A (es) Derivado de benzotriazol.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2021003427A (es) Nuevos oxadiazoles.
JOP20220006A1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
PH12020550252A1 (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA202192646A1 (ru) Лиофилизированная композиция, содержащая соединение бензоазепина